{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-034082","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-05-12T20:03:05+00:00","discovered_at":"2026-05-12T20:04:00.383970+00:00","generated_at":"2026-05-12T20:06:25.969584+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TriSalus Q1 revenue $8.9M (-2.9% YoY); revises FY 2026 guidance to $54-57M","bullets":["Revenue $8.9M, down 2.9% YoY; gross margin improved to 86.2% from 83.7%.","Net income $1.5M ($0.03 EPS) on $11.3M non-cash derivative gains; adj. EBITDA loss $5.8M.","Raised $46M in equity; cash $56.6M to fund commercial expansion and pipeline.","2026 revenue guidance revised to $54-57M, reflecting commercial expansion and TriNav Advance FDA clearance delay.","Appointed Richard Marshall as Chief Medical Officer effective June 29, 2026; added board member Michael Stansky."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-034082","json":"https://secwatch.observer/filing/0001628280-26-034082.json","markdown":"https://secwatch.observer/filing/0001628280-26-034082.md","text":"https://secwatch.observer/filing/0001628280-26-034082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/0001628280-26-034082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026034082/tlsi-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:06:25.969584+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}